EHMT2 and chronic myelogenous leukemia, BCR-ABL1 positive: We have found that inhibiting the H3K9me2 specific methyltransferases, EHMT1 and EHMT2, either with chemical inhibitors or RNAi sensitizes CML cell lines to interferon treatment.